Adverse Event Burden, Resource Use, and Costs Associated with Immunosuppressant Medications for the Treatment of Systemic Lupus Erythematosus: A Systematic Literature Review

Table 2

Discontinuation rates by intervention and study type.

	MMF	MTX	AZA	IVC	Oral CYC	CsA
RCTs (𝑛=11)	1.4–13%	12.2%	2.3–20%	2.9–7.7%	9.7–44.4%	13.9–17.0%
Observational (𝑛=11)	0–16.7%	8.3–11%	19–21.8%	1.9–18.8%	5.6%	16.1%

AZA: azathioprine; CsA: cyclosporine; CYC: cyclophosphamide; IVC: intravenous cyclophosphamide; MMF: mycophenolate mofetil; MTX: methotrexate; N/A: not available; RCT: randomized controlled trial.